PL2711371T3 - Zastosowanie steroidów pregnanowych i androstanowych do wytwarzania kompozycji farmaceutycznej do leczenia zaburzeń oun - Google Patents
Zastosowanie steroidów pregnanowych i androstanowych do wytwarzania kompozycji farmaceutycznej do leczenia zaburzeń ounInfo
- Publication number
- PL2711371T3 PL2711371T3 PL13198584T PL13198584T PL2711371T3 PL 2711371 T3 PL2711371 T3 PL 2711371T3 PL 13198584 T PL13198584 T PL 13198584T PL 13198584 T PL13198584 T PL 13198584T PL 2711371 T3 PL2711371 T3 PL 2711371T3
- Authority
- PL
- Poland
- Prior art keywords
- pregnane
- manufacture
- treatment
- pharmaceutical composition
- cns disorders
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
- C07J7/008—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21
- C07J7/009—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21 by only one oxygen atom doubly bound
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, ***e
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
- C07J1/0003—Androstane derivatives
- C07J1/0011—Androstane derivatives substituted in position 17 by a keto group
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
- C07J41/0016—Oximes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of only two carbon atoms, e.g. pregnane derivatives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
- C07J5/0007—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond not substituted in position 17 alfa
- C07J5/0015—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond not substituted in position 17 alfa not substituted in position 16
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
- C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
- C07J7/001—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group
- C07J7/0015—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa
- C07J7/002—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa not substituted in position 16
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
- C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
- C07J7/0065—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by an OH group free esterified or etherified
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
- C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
- C07J7/0065—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by an OH group free esterified or etherified
- C07J7/007—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by an OH group free esterified or etherified not substituted in position 17 alfa
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Pulmonology (AREA)
- Ophthalmology & Optometry (AREA)
- Child & Adolescent Psychology (AREA)
- Anesthesiology (AREA)
- Psychology (AREA)
- Reproductive Health (AREA)
- Immunology (AREA)
- Nutrition Science (AREA)
- Rheumatology (AREA)
- Steroid Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US86065806P | 2006-11-21 | 2006-11-21 | |
EP07835459.4A EP2097437B1 (en) | 2006-11-21 | 2007-11-20 | The use of pregnane and androstane steroids for the manufacture of a pharmaceutical composition for the treatment of cns disorders |
EP13198584.8A EP2711371B1 (en) | 2006-11-21 | 2007-11-20 | The use of pregnane and androstane steroids for the manufacture of a pharmaceutical composition for the treatment of CNS disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
PL2711371T3 true PL2711371T3 (pl) | 2018-06-29 |
Family
ID=39429970
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL07835459T PL2097437T3 (pl) | 2006-11-21 | 2007-11-20 | Zastosowanie steroidów pregnanowych i androstanowych do wytwarzania kompozycji farmaceutycznej do leczenia zaburzeń OUN |
PL14154304T PL2792681T3 (pl) | 2006-11-21 | 2007-11-20 | Zastosowanie steroidów pregnanowych i androstanowych do wytwarzania kompozycji farmaceutycznej do leczenia zaburzeń CNS |
PL13198584T PL2711371T3 (pl) | 2006-11-21 | 2007-11-20 | Zastosowanie steroidów pregnanowych i androstanowych do wytwarzania kompozycji farmaceutycznej do leczenia zaburzeń oun |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL07835459T PL2097437T3 (pl) | 2006-11-21 | 2007-11-20 | Zastosowanie steroidów pregnanowych i androstanowych do wytwarzania kompozycji farmaceutycznej do leczenia zaburzeń OUN |
PL14154304T PL2792681T3 (pl) | 2006-11-21 | 2007-11-20 | Zastosowanie steroidów pregnanowych i androstanowych do wytwarzania kompozycji farmaceutycznej do leczenia zaburzeń CNS |
Country Status (16)
Country | Link |
---|---|
US (9) | US8580983B2 (pl) |
EP (4) | EP2097437B1 (pl) |
JP (5) | JP5386362B2 (pl) |
AU (1) | AU2007322423C1 (pl) |
BR (2) | BR122013033954B8 (pl) |
CA (2) | CA2664126C (pl) |
DK (3) | DK2792681T3 (pl) |
ES (3) | ES2543841T3 (pl) |
HU (3) | HUE033037T2 (pl) |
IN (1) | IN2014DN02014A (pl) |
MX (1) | MX2009005335A (pl) |
PL (3) | PL2097437T3 (pl) |
PT (1) | PT2097437E (pl) |
RU (1) | RU2458065C2 (pl) |
SI (1) | SI2097437T1 (pl) |
WO (1) | WO2008063128A1 (pl) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2097437B1 (en) | 2006-11-21 | 2015-05-27 | Umecrine Cognition AB | The use of pregnane and androstane steroids for the manufacture of a pharmaceutical composition for the treatment of cns disorders |
CN101585862B (zh) * | 2008-05-20 | 2014-12-17 | 梅克芳股份公司 | 甾族化合物 |
AU2011205821B2 (en) | 2010-01-14 | 2013-07-25 | Umecrine Mood Ab | A pharmaceutical composition comprising 3-beta-hydroxy-5-alpha-pregnan-20-one with improved storage and solubility properties |
EP2566482A1 (en) * | 2010-05-07 | 2013-03-13 | Institut National de la Santé et de la Recherche Médicale | Progesterone receptor antagonists and uses thereof |
SI2925770T1 (sl) * | 2012-11-28 | 2017-07-31 | Institut National De La Sante Et De La Recherche Medicale(Inserm) | 3-(4'-substituirani)-benzil-eter derivati pregnenolona |
PT3461834T (pt) | 2013-03-13 | 2021-09-10 | Sage Therapeutics Inc | Esteroides neuroativos |
CA2935015C (en) | 2014-01-29 | 2022-05-31 | Umecrine Cognition Ab | Steroid compound for use in the treatment of hepatic encephalopathy |
PT3224269T (pt) * | 2014-11-27 | 2020-06-01 | Sage Therapeutics Inc | Composições e métodos para tratamento de distúrbios do snc |
TWI748936B (zh) * | 2015-01-12 | 2021-12-11 | 瑞典商優鎂奎認知Ab公司 | 新穎化合物 |
CN108135911B (zh) | 2015-07-06 | 2021-06-25 | 萨奇治疗股份有限公司 | 氧甾醇及其使用方法 |
DE102015120587A1 (de) | 2015-11-26 | 2017-06-01 | Brandenburgische Technische Universität Cottbus-Senftenberg | Verfahren zur selektiven Oxygenierung von Testosteron und Testosteron-ähnlichen Steroiden |
ES2921010T3 (es) | 2016-04-01 | 2022-08-16 | Sage Therapeutics Inc | Oxisteroles y procedimientos de uso de los mismos |
WO2017193046A1 (en) | 2016-05-06 | 2017-11-09 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
US10278977B2 (en) | 2016-06-06 | 2019-05-07 | Umecrine Cognition Ab | Methods for treating hypersomnolence |
JP2019532079A (ja) | 2016-10-18 | 2019-11-07 | セージ セラピューティクス, インコーポレイテッド | オキシステロールおよびその使用方法 |
US11149054B2 (en) | 2016-10-18 | 2021-10-19 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
EP3579842A4 (en) | 2017-02-10 | 2020-12-23 | Asarina Pharma AB | 3-BETA-HYDROXY-5-ALPHA-PRÉGNAN-20-ONE FOR USE IN THE TREATMENT OF ESSENTIAL TREMMENTS |
BR112019015362A2 (pt) | 2017-02-10 | 2020-10-20 | Asarina Pharma Ab | 3-beta-hidroxi-5-alfa-pregnan-20-ona para uso em tratamento médico |
EP3716954A1 (en) | 2017-11-27 | 2020-10-07 | Umecrine Cognition AB | Pharmaceutical formulation of 3 -ethynyl-3 -hydroxyandrostan-17-one oxime |
CN111918657A (zh) | 2018-04-05 | 2020-11-10 | 阿沙里那制药有限公司 | 用于治疗物质戒断障碍的gaba-a拮抗剂 |
CN112457362B (zh) * | 2019-09-06 | 2023-09-19 | 上海青东生物科技有限公司 | 一种卤代四环三萜衍生物及其制备与应用 |
EP4079307A1 (en) | 2021-04-20 | 2022-10-26 | Umecrine Cognition AB | New medical use |
WO2023083979A1 (en) | 2021-11-10 | 2023-05-19 | Umecrine Ab | 3.beta.-hydroxy, 3.alpha.-ethyl steroids for modulation of the alpha-3 subtype of the gaba-a receptor |
WO2023083980A1 (en) | 2021-11-10 | 2023-05-19 | Umecrine Ab | Steroid as a modulator of gabaa receptor |
CA3237550A1 (en) | 2021-11-10 | 2023-05-19 | Umecrine Ab | 3.alpha.-substituted 3.beta.-hydroxy 17-oximated androstane compound for modulation of the alpha-3 subtype of the gaba-a receptor |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR1463755A (fr) * | 1960-01-26 | 1966-07-22 | Nouveaux stéroïdes de la série de l'androstane et leur procédé de préparation | |
US3152121A (en) | 1962-03-16 | 1964-10-06 | Upjohn Co | 20-ketals of 3-hydroxy-5 beta-pregnan-20-one |
CH491889A (de) | 1966-10-22 | 1970-06-15 | Richter Gedeon Vegyeszet | Verfahren zur Herstellung von Steroiden |
US5120723A (en) * | 1987-08-25 | 1992-06-09 | University Of Southern California | Method, compositions, and compounds for modulating brain excitability |
US5232917A (en) | 1987-08-25 | 1993-08-03 | University Of Southern California | Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series |
US5234603A (en) | 1991-06-04 | 1993-08-10 | Analytical Development Corporation | Methods employing a zirconium salt for use in wastewater treatment |
AU698834B2 (en) * | 1993-05-24 | 1998-11-12 | Purdue Pharma Ltd. | Methods and compositions for inducing sleep |
US5939545A (en) | 1994-02-14 | 1999-08-17 | Cocensys, Inc. | Method, compositions, and compounds for allosteric modulation of the gaba receptor by members of the androstane and pregnane series |
ATE195654T1 (de) | 1994-02-14 | 2000-09-15 | Euro Celtique Sa | Androstane und pregnane zur allosterischen modulation des gaba-rezeptors |
ATE198753T1 (de) * | 1994-11-23 | 2001-02-15 | Cocensys Inc | Androstan- und pregnanserien für die allosterische modulation des gaba-rezeptors |
BR9608592A (pt) | 1995-06-06 | 1999-06-29 | Cocensys Inc | Esteróides neuroativos da série do androstano e do pregnano |
AU3967297A (en) * | 1996-08-01 | 1998-02-25 | Cocensys, Inc. | Use of gaba and nmda receptor ligands for the treatment of migraine headache |
AU756001B2 (en) | 1998-03-11 | 2003-01-02 | Umecrine Mood Ab | Epiallopregnanolone in the treatment of CNS disorders |
WO1999052532A1 (en) | 1998-04-14 | 1999-10-21 | Pharmadigm, Inc. | Method for reducing central nervous system impairment |
US20030060425A1 (en) * | 1998-11-24 | 2003-03-27 | Ahlem Clarence N. | Immune modulation method using steroid compounds |
CZ294278B6 (cs) * | 1999-11-25 | 2004-11-10 | Ústav organické chemie a biochemie AV ČR | Neuroaktivní steroidy a způsob jejich přípravy |
GB2363984A (en) * | 2000-06-29 | 2002-01-16 | Hunter Fleming Ltd | Protection against neuronal damage using 3-hydroxy-7 -hydroxy steroids and 3-oxo-7 -hydroxy steroids |
GB2363983A (en) * | 2000-06-29 | 2002-01-16 | Hunter Fleming Ltd | Protection against neuronal damage using 7-hydroxyepiandrosterone |
FR2831441B1 (fr) | 2001-10-25 | 2003-12-26 | Oreal | Utilisation cosmetique de derives de la dhea |
EP1310258A1 (en) | 2001-11-08 | 2003-05-14 | Etienne-Emile Baulieu | Enantiomers of steroids for the enhancement of memory and cognitive function |
SE0104423D0 (sv) | 2001-12-27 | 2001-12-27 | Umecrine Ab | Pregnane steroids and their use in the treatment of CNS disorders |
ES2423493T3 (es) * | 2004-11-18 | 2013-09-20 | Umecrine Ab | Antagonistas de los GABA-esteroides y su uso para el tratamiento de trastornos del SNC |
EP2097437B1 (en) | 2006-11-21 | 2015-05-27 | Umecrine Cognition AB | The use of pregnane and androstane steroids for the manufacture of a pharmaceutical composition for the treatment of cns disorders |
EP2566482A1 (en) | 2010-05-07 | 2013-03-13 | Institut National de la Santé et de la Recherche Médicale | Progesterone receptor antagonists and uses thereof |
-
2007
- 2007-11-20 EP EP07835459.4A patent/EP2097437B1/en active Active
- 2007-11-20 JP JP2009537124A patent/JP5386362B2/ja not_active Expired - Fee Related
- 2007-11-20 HU HUE14154304A patent/HUE033037T2/hu unknown
- 2007-11-20 HU HUE13198584A patent/HUE036410T2/hu unknown
- 2007-11-20 HU HUE07835459A patent/HUE026961T2/en unknown
- 2007-11-20 ES ES07835459.4T patent/ES2543841T3/es active Active
- 2007-11-20 BR BR122013033954A patent/BR122013033954B8/pt not_active IP Right Cessation
- 2007-11-20 CA CA2664126A patent/CA2664126C/en active Active
- 2007-11-20 DK DK14154304.1T patent/DK2792681T3/en active
- 2007-11-20 PT PT78354594T patent/PT2097437E/pt unknown
- 2007-11-20 US US11/943,555 patent/US8580983B2/en not_active Expired - Fee Related
- 2007-11-20 SI SI200731681T patent/SI2097437T1/sl unknown
- 2007-11-20 DK DK07835459.4T patent/DK2097437T3/en active
- 2007-11-20 EP EP13198608.5A patent/EP2711372A1/en not_active Withdrawn
- 2007-11-20 EP EP14154304.1A patent/EP2792681B1/en not_active Not-in-force
- 2007-11-20 BR BRPI0718945A patent/BRPI0718945B8/pt active IP Right Grant
- 2007-11-20 CA CA2833976A patent/CA2833976C/en active Active
- 2007-11-20 AU AU2007322423A patent/AU2007322423C1/en active Active
- 2007-11-20 PL PL07835459T patent/PL2097437T3/pl unknown
- 2007-11-20 IN IN2014DEN2014 patent/IN2014DN02014A/en unknown
- 2007-11-20 PL PL14154304T patent/PL2792681T3/pl unknown
- 2007-11-20 ES ES14154304.1T patent/ES2607852T3/es active Active
- 2007-11-20 RU RU2009107537/04A patent/RU2458065C2/ru active
- 2007-11-20 MX MX2009005335A patent/MX2009005335A/es active IP Right Grant
- 2007-11-20 PL PL13198584T patent/PL2711371T3/pl unknown
- 2007-11-20 WO PCT/SE2007/050876 patent/WO2008063128A1/en active Application Filing
- 2007-11-20 EP EP13198584.8A patent/EP2711371B1/en not_active Not-in-force
- 2007-11-20 ES ES13198584.8T patent/ES2662500T3/es active Active
- 2007-11-20 DK DK13198584.8T patent/DK2711371T3/en active
-
2012
- 2012-12-17 US US13/716,984 patent/US20130102579A1/en not_active Abandoned
- 2012-12-17 US US13/716,794 patent/US20130102578A1/en not_active Abandoned
-
2013
- 2013-03-07 US US13/788,006 patent/US20140011792A1/en not_active Abandoned
- 2013-03-07 US US13/788,074 patent/US20140011793A1/en not_active Abandoned
- 2013-03-07 US US13/787,924 patent/US8853190B2/en active Active
- 2013-03-22 US US13/848,782 patent/US9200028B2/en active Active
- 2013-05-07 JP JP2013097486A patent/JP5918170B2/ja active Active
- 2013-05-07 JP JP2013097485A patent/JP2013173781A/ja active Pending
- 2013-05-07 JP JP2013097487A patent/JP5657052B2/ja active Active
-
2015
- 2015-03-11 JP JP2015047791A patent/JP2015147774A/ja active Pending
- 2015-07-10 US US14/796,301 patent/US20150315231A1/en not_active Abandoned
- 2015-11-19 US US14/945,575 patent/US20160272670A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUE036410T2 (hu) | Pregnán és androsztán szteroidok alkalmazása CNS rendellenességek kezelésére szolgáló gyógyszerkészítmény elõállítására | |
SI1919450T1 (sl) | Liposomski sestavek, ki vsebuje antihistaminik in kortikosteroid, in njegova uporaba za izdelavo zdravila za zdravljenje rinitisa in sorodnih motenj | |
SI2027140T1 (sl) | Industrijski proces za sintezo 17 alfa -acetoksi-11 beta -(4-(n,n- dimetil-amino)-fenil)-19-norpregna-4,9-dien-3,20-diona in novi intermediati postopka | |
EP2099449A4 (en) | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND PREVENTION OF DISEASES THAT COME WITH IMPOTENCE | |
HK1133651A1 (en) | Indazolyl amide derivatives for the treatment of glucocorticoid receptor mediated disorders | |
PT2393477T (pt) | Uso de uma composição glicocorticoide para o tratamento de asma severa e não controlada | |
IL178775A (en) | Pharmaceuticals containing glucocorticoid for use in the treatment of disorders requiring acute glucocorticoid therapy | |
IL221764A (en) | Use of bile acid sulfate to make pharmaceutical preparations for the treatment of fxr-related diseases | |
IL193936A0 (en) | Compositions and methods for the treatment of immunoinflammatory disorders | |
EP2318005A4 (en) | NEUROPROTECTIVE AGENTS FOR THE PREVENTION AND TREATMENT OF NEURODEEGENERATIVE DISEASES | |
EP1988777A4 (en) | PYRAZOLE FOR THE TREATMENT OF ADIPOSITAS AND OTHER CNS DISEASES | |
EP2044108A4 (en) | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND TREATMENT OF ISCHEMIC SUDIDS AND METHOD FOR THEIR ADMINISTRATION | |
EP1996218A4 (en) | METHODS AND COMPOSITIONS FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS | |
HK1134821A1 (en) | Amino derivatives of androstanes and androstenes as medicaments for cardiovascular disorders | |
EP2004216A4 (en) | AGENT FOR THE TREATMENT OF HORMONO-DEPENDENT DISORDERS AND USES THEREOF | |
EP2056857A4 (en) | PHARMACEUTICAL COMPOSITIONS WITH CCL2 AND THEIR USE IN THE TREATMENT OF INFLAMMATION | |
HK1137357A1 (en) | Use of a composition comprising formoterol and beclometasone dipropionate in the manufacture of a pharmaceutical for the prevention and or treatment of an exacerbation of asthma | |
EP2077838A4 (en) | METHODS FOR TREATING A-RELATED DISORDERS AND COMPOSITIONS THEREFOR | |
IL200044A (en) | Tricyclic compounds as modulators of a glucocorticoid receptor and their use in the preparation of drugs for the treatment of diseases | |
EP2403501A4 (en) | PREGNENOLONSULFATE FOR THE TREATMENT OF NEUROLOGICAL DISEASES | |
IL202205A (en) | Process for the preparation of steroids converted at position 17α by 3-hydroxypropyl and at position 17ß - by hydroxy from the corresponding 14-oxo history and intermediates obtained in this process | |
IL204957A (en) | Derivatives of 3 - (aminoalkoxyimino) - androstane and androsten | |
AU2006906505A0 (en) | Agent for the treatment of hormone-dependent disorders and uses thereof | |
HU0600815D0 (en) | Pharmaceutical composition for the treatment of obstructive and inflammatory disorders of the respiratory tract | |
AU2007906680A0 (en) | Methods and compositions for the treatment of phosphatase-related disorders |